139 related articles for article (PubMed ID: 12737328)
21. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
22. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts.
Takeshita S; Namba N; Zhao JJ; Jiang Y; Genant HK; Silva MJ; Brodt MD; Helgason CD; Kalesnikoff J; Rauh MJ; Humphries RK; Krystal G; Teitelbaum SL; Ross FP
Nat Med; 2002 Sep; 8(9):943-9. PubMed ID: 12161749
[TBL] [Abstract][Full Text] [Related]
23. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
24. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
26. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
27. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
28. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.
Shinoda K; Sugiyama E; Taki H; Harada S; Mino T; Maruyama M; Kobayashi M
Bone; 2003 Oct; 33(4):711-20. PubMed ID: 14555277
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
30. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.
Quinn JM; Elliott J; Gillespie MT; Martin TJ
Endocrinology; 1998 Oct; 139(10):4424-7. PubMed ID: 9751528
[TBL] [Abstract][Full Text] [Related]
31. Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures.
Sarma U; Flanagan AM
Blood; 1996 Oct; 88(7):2531-40. PubMed ID: 8839845
[TBL] [Abstract][Full Text] [Related]
32. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia.
Olivier BJ; Schoenmaker T; Mebius RE; Everts V; Mulder CJ; van Nieuwkerk KM; de Vries TJ; van der Merwe SW
Hepatology; 2008 Jan; 47(1):259-67. PubMed ID: 18022900
[TBL] [Abstract][Full Text] [Related]
33. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.
Okada Y; Lorenzo JA; Freeman AM; Tomita M; Morham SG; Raisz LG; Pilbeam CC
J Clin Invest; 2000 Mar; 105(6):823-32. PubMed ID: 10727451
[TBL] [Abstract][Full Text] [Related]
34. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
[TBL] [Abstract][Full Text] [Related]
35. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
36. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts.
de Vries TJ; Schoenmaker T; Wattanaroonwong N; van den Hoonaard M; Nieuwenhuijse A; Beertsen W; Everts V
J Cell Biochem; 2006 May; 98(2):370-82. PubMed ID: 16440316
[TBL] [Abstract][Full Text] [Related]
37. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages.
Itonaga I; Sabokbar A; Murray DW; Athanasou NA
Ann Rheum Dis; 2000 Jan; 59(1):26-31. PubMed ID: 10627423
[TBL] [Abstract][Full Text] [Related]
38. Identification of multiple osteoclast precursor populations in murine bone marrow.
Jacquin C; Gran DE; Lee SK; Lorenzo JA; Aguila HL
J Bone Miner Res; 2006 Jan; 21(1):67-77. PubMed ID: 16355275
[TBL] [Abstract][Full Text] [Related]
39. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
40. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
Chu K; Snyder R; Econs MJ
J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
